ClinicalTrials.gg
RecruitingNCT05979545RAPIDUpdated Oct 22, 2026

EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

A Phase 4 interventional study of Rapid Diagnostics in Blood Stream Infections, Ventilator Associated Pneumonia and Healthcare Associated Infection, sponsored by National University of Singapore. Recruiting at 21 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by National University of Singapore · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Oct 22, 2026First sites in 4 new countriesSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,526
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

RAPID is an investigator initiated Phase 4, multinational, multicentre, open-label, randomised controlled superiority trial evaluating the clinical impact of rapid microbiological diagnostics combined with antimicrobial stewardship and early targeted antibiotic therapy compared with standard-of-care diagnostics and antibiotics.

Hospitalised adult patients with bloodstream infections, hospital-acquired pneumonia or ventilator-associated pneumonia are randomised in a 1:1 ratio to the intervention or control arm.

The main analysis population comprises patients with infections caused by Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales. A secondary analysis population includes patients with infections caused by other specified multidrug-resistant Gram-negative organisms.

Patients will be randomised to either a control or intervention arm. Patients randomised to the intervention arm will have relevant specimens analysed by rapid microbiological diagnostics and will have early availability of ceftazidime-avibactam if appropriate. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics will be available to these patients as per usual institutional practice.

The primary outcome is a composite of all-cause mortality or absence of improvement in Sequential Organ Failure Assessment (SOFA) score at Day 14 following the index culture.

Read the detailed description

The RAPID trial integrates rapid molecular diagnostics with locally adapted antimicrobial stewardship guidelines to facilitate timely identification of Gram-negative pathogens, detection of antimicrobial resistance genes and appropriate antibiotic selection.

In the intervention arm, positive blood cultures will undergo testing using the BioFire Blood Culture Identification 2 (BCID2) Panel, while respiratory specimens from patients with hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) will be tested using the BioFire FilmArray Pneumonia Panel or Pneumonia Plus Panel. Rapid diagnostic testing will be initiated within four hours of Gram-negative bacilli being observed on Gram stain, alongside conventional microbiological testing. Clinicians will receive guidance on interpreting resistance gene results and selecting antibiotics according to locally adapted antimicrobial stewardship protocols. Ceftazidime-avibactam will be available for patients with Pseudomonas aeruginosa or Enterobacterales with detected carbapenemase genes, subject to predefined eligibility criteria and local regulatory approval. Antibiotic treatment may subsequently be modified based on conventional susceptibility testing and clinical judgement.

In the control arm, microbiological investigations and antibiotic treatment will follow standard institutional practices, with antibiotic selection determined by the treating clinicians.

Study population assignment will be based on conventional microbiological identification and antimicrobial susceptibility testing in both arms. The main analysis population will comprise patients with bloodstream infections, HAP or VAP caused by Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales. The secondary analysis population will include patients with infections caused by ceftriaxone/cefotaxime/ceftazidime-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex or Stenotrophomonas maltophilia. Patients in the secondary population will receive antibiotics according to locally adapted antimicrobial stewardship guidelines rather than protocol-directed ceftazidime-avibactam.

Participants will be followed for 60 days following the index culture, with assessments of clinical outcomes, mortality, antibiotic utilisation, microbiological outcomes, antimicrobial resistance and functional status. Repeat microbiological cultures will be performed to assess bacterial persistence, and initial bacterial isolates will undergo antimicrobial susceptibility testing and whole-genome sequencing at a central laboratory.

02

Conditions studied

  • Blood Stream Infections
  • Ventilator Associated Pneumonia
  • Healthcare Associated Infection
  • Carbapenem-Resistant Enterobacteriaceae Infection
  • Hospital-acquired Pneumonia

Keywords

  • rapid diagnostics
  • ceftazidime-avibactam
  • carbapenemase producing Enterobacterales
  • hospital-acquired
  • MDR
  • AMR
  • ASP
  • CRE
  • BCID2
  • PN Plus
03

In context

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

This study's planned enrollment of 1,526 is above the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.

Browse Pneumonia, Ventilator-Associated studies →

Lead sponsor

National University of Singapore is the lead sponsor of 212 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients aged 18 years or older (21 years or older in Singapore) who meet at least one of the following criteria:

    • At risk of developing bloodstream infection, hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP) due to Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales; OR
    • Blood culture bottles showing Gram-negative bacilli on Gram stain; OR
    • Suspected HAP or VAP with respiratory specimens showing Gram-negative bacteria on Gram stain.
  2. For randomisation, all of the following criteria must be fulfilled:

    • Written obtained from the participant or their authorised representative.
    • An appropriate blood or respiratory specimen received by the participating microbiology laboratory, with Gram-negative bacilli detected on Gram stain.
    • Patients with HAP or VAP must fulfil the US Centers for Disease Control and Prevention National Healthcare Safety Network (CDC NHSN) criteria.
    • No exclusion criteria are met.

Exclusion criteria

Exclusion Criteria:

  1. shock or comorbid condition such that the patient is not expected to survive more than 48 hours.
  2. Suspected catheter-related bloodstream infection where the implicated vascular catheter cannot be removed.
  3. Treatment is not intended to cure the infection.
  4. Infection requiring prolonged antibiotic treatment (more than two weeks).
  5. Incarceration in a correctional facility.
  6. Previous enrolment in the RAPID trial within the preceding 60 days.
  7. Patients younger than 18 years (younger than 21 years in Singapore).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,526 participants (estimated)

Study arms

  • Active comparator
    Intervention

    Rapid microbiological diagnostics using the BioFire BCID2 Panel for bloodstream infections or BioFire FilmArray Pneumonia/Pneumonia Plus Panel for respiratory infections, combined with locally adapted antimicrobial stewardship and early targeted antibiotic therapy. Samples from patients randomised to the intervention arm will undergo the BioFire FilmArray systems. Patients will be then administered with the study drug, ceftazidime-avibactam when Pseudomonas aeruginosa or carbapenemase producing Enterobacterales detected. Appropriate antibiotic must be administered according to predefined antibiotic stewardship guidelines within 24 hours of the Gram stain being performed on the index specimen.

    Diagnostic Test: Rapid Diagnostics

  • No intervention
    Control

    Standard-of-care microbiological diagnostics and antibiotic treatment according to local clinical practice and treating physician discretion. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics treatment will be administered as per usual institutional practice from hospital supplies.

Interventions

  • Diagnostic testRapid Diagnostics

    Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Rapid diagnostic testing must be initiated as soon as Gram-negative bacilli is detected on Gram stain, and appropriate antibiotic must be administered according to predefined antibiotic stewardship guidelines within 24 hours of the Gram stain being performed on the index respiratory or blood culture specimen, that defined entry into the trial. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.

    Also known as: BioFire FilmArray BCID2, BioFire FilmArray Pneumonia Plus Panel, BioFire FilmArray Pneumonia Panel

06

What researchers measure

Primary outcomes

  1. Composite of All-Cause Mortality or Absence of SOFA Score Improvement at Day 14

    Proportion of participants experiencing all-cause mortality within 14 days of the index blood or respiratory culture, or absence of improvement in Sequential Organ Failure Assessment (SOFA) score at Day 14. SOFA improvement is defined according to the prespecified baseline SOFA criteria in the study protocol.

    Time frame: Day 14 following index culture.

Secondary outcomes

  1. Clinical Response at Day 7 and Day 14

    Proportion of participants achieving clinical response at Day 7 and Day 14 following the index culture, assessed using clinical stability indicators, including temperature \<38°C for at least 48 hours and systolic blood pressure \>90 mmHg without inotropic support.

    Time frame: Day 7 and Day 14 following index culture

  2. All-Cause Mortality at Day 14, Day 28 and Day 60

    Proportion of participants who die from any cause within 14, 28 and 60 days following collection of the index blood or respiratory culture specimen.

    Time frame: Day 14, Day 28 and Day 60 following index culture

  3. Functional Status and Health-Related Quality of Life

    Functional status and health-related quality of life will be assessed using the Functional Bacteraemia and Infection Score (FBIS) and EuroQol 5-Dimension 3-Level questionnaire (EQ-5D-3L), respectively, at Day 14, Day 28 and Day 60 following the index culture.

    Time frame: Day 14, Day 28 and Day 60 following index culture

  4. Desirability of Outcome Ranking (DOOR) at Day 28

    Participant outcomes will be assessed using a five-level Desirability of Outcome Ranking (DOOR) composite measure incorporating survival status at Day 28, absence of early clinical response and late infectious complications. Scores range from 1 to 5, with lower scores indicating more desirable outcomes.

    Time frame: Day 28 following index culture

  5. Implementation Costs and Health Economic Outcomes

    Implementation costs will be evaluated using hospital and intensive care unit (ICU) length of stay within 60 days following randomisation. Within-trial and modelled economic evaluations will assess costs and health outcomes associated with rapid diagnostics and antimicrobial stewardship compared with standard care. Cost-effectiveness will be expressed using incremental cost-effectiveness ratios and net monetary benefits.

    Time frame: Within 60 days following randomisation for within-trial resource utilisation; modelled time horizon to be confirmed.

  6. Days Alive and Out of Hospital Within 60 Days

    Number of days participants are alive and out of hospital during the 60-day period following the index culture.

    Time frame: Up to Day 60 following index culture

  7. Length of Intensive Care Unit Stay

    Duration of intensive care unit (ICU) stay, measured in days, during the 60-day follow-up period.

    Time frame: Up to Day 60 following index culture

  8. Length of Hospital Stay

    Duration of hospitalisation, measured in days, during the 60-day follow-up period.

    Time frame: Up to Day 60 following index culture

  9. Duration of Mechanical Ventilation

    Total number of days participants require mechanical ventilation during the 60-day follow-up period

    Time frame: Up to Day 60 following index culture

  10. Type of Accommodation Upon Hospital Discharge

    Type of accommodation or care setting to which participants are discharged following hospitalisation.

    Time frame: At hospital discharge, assessed within 60 days following index culture

  11. Persistence of Bacteraemia at Day 4

    Proportion of participants with bloodstream infection who have persistent bacterial growth in repeat blood cultures collected on Day 4 following the index culture.

    Time frame: Day 4 following index culture

  12. Microbiological Growth in Respiratory Cultures at Day 7

    Proportion of participants with hospital-acquired pneumonia or ventilator-associated pneumonia who have bacterial growth detected in repeat respiratory cultures collected on Day 7 following the index culture.

    Time frame: Day 7 following index culture

  13. Development of Resistance to Meropenem or Ceftazidime-Avibactam

    Proportion of participants with bacterial isolates demonstrating development of resistance to meropenem or ceftazidime-avibactam during follow-up, as determined by antimicrobial susceptibility testing.

    Time frame: Up to Day 28 following index culture

  14. Incidence of Acute Kidney Injury

    Proportion of participants developing acute kidney injury during the 28-day follow-up period.

    Time frame: Up to Day 28 following index culture

  15. Incidence of Clostridioides difficile Diarrhoea

    Proportion of participants developing Clostridioides difficile-associated diarrhoea during the 28-day follow-up period.

    Time frame: Up to Day 28 following index culture

  16. Time From Index Culture to Active Antibiotic Therapy

    Time elapsed, measured in hours, between collection of the index culture specimen and administration of the first antibiotic with activity against the causative pathogen.

    Time frame: From index culture collection to initiation of active antibiotic therapy

  17. Number of Days on Antibiotic Treatment Within 28 Days

    Total number of days of antibiotic treatment administered to participants during the first 28 days following the index culture.

    Time frame: Up to Day 28 following index culture

  18. Antibiotic Treatment Modification Following Microbiological Diagnosis

    Proportion of participants whose antibiotic treatment is modified within seven days following availability of microbiological diagnostic results.

    Time frame: Within 7 days following microbiological diagnostic results

  19. Time to Detection of Carbapenemase Production or Carbapenem Resistance

    Time elapsed, measured in hours, between collection of the index specimen and reporting of carbapenemase production and/or carbapenem resistance in the causative bacterial isolate.

    Time frame: From index specimen collection to reporting of microbiological results

  20. Time to Detection of Third-Generation Cephalosporin Resistance

    Time elapsed, measured in hours, between collection of the index specimen and reporting of resistance to ceftriaxone, cefotaxime or ceftazidime in Enterobacterales isolates.

    Time frame: From index specimen collection to reporting of microbiological results

  21. Time to Identification of Other Multidrug-Resistant Gram-Negative Pathogens

    Time elapsed, measured in hours, between collection of the index specimen and identification of Acinetobacter baumannii-calcoaceticus complex or Stenotrophomonas maltophilia.

    Time frame: From index specimen collection to reporting of microbiological results

Other outcomes

  1. Whole-Genome Sequencing of Causative Bacterial Isolates

    Initial bacterial isolates collected from participants will undergo whole-genome sequencing at a central laboratory for genotypic characterisation of the causative pathogens.

    Time frame: Baseline (index culture)

07

Study locations

21 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the primary publication of the RAPID trial may be shared with qualified researchers following approval of a methodologically sound proposal, subject to applicable ethical, regulatory, institutional and contractual requirements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 12 months after publication of the primary trial results and remaining available for 5 years.

Access criteria: Requests will be reviewed by the RAPID trial investigators and/or the relevant institutional data access authority. Approved researchers must enter into an appropriate data-sharing agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2023 (actual). Primary completion is estimated for Oct 2027, 46 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Oct 2026 → Oct 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 7, 2023
StartActual
Dec 12, 2023
Primary completionEst.
Oct 31, 2027was Oct 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added, 1 site removed — first sites in India, Singapore, South Korea and Turkey (Türkiye). 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • University Malaya Medical Centre · Kuala Lumpur, MalaysiaNot yet recruiting→Recruiting
  • Sunpasitthiprasong Hospital · Ubon Ratchathani, ThailandNot yet recruiting→Recruiting
Show 18 added (4 Malaysia, 4 South Korea, 3 Taiwan, 3 Thailand, 2 Singapore, 1 India, 1 Turkey (Türkiye))
  • Christian Medical College Vellore · Vellore, India
  • Hospital Pulau Pinang · George Town, Malaysia
  • Hospital Raja Permaisuri Bainun · Ipoh, Malaysia
  • Sarawak General Hospital · Kuching, Malaysia
  • Hospital Seberang Jaya · Seberang Jaya, Malaysia
  • National University Hospital · Singapore, Singapore
  • Tan Tock Seng Hospital · Singapore, Singapore
  • Korea University Ansan Hospital · Ansan, South Korea
  • Soonchunhyang University Cheonan Hospital · Cheonan, South Korea
  • Kyungpook National University Chilgok Hospital · Daegu, South Korea
  • Seoul National University Bundang Hospital · Seongnam, South Korea
  • Kaohsiung Medical University Hospital · Kaohsiung City, Taiwan
  • Kaohsiung Veterans General Hospital · Kaohsiung City, Taiwan
  • National Taiwan University Hospital · Taipei, Taiwan
  • Siriraj Hospital · Bangkok, Thailand
  • Songklanagarind Hospital · Hat Yai, Thailand
  • Srinagarind Hospital, Khon Kaen University · Khon Kaen, Thailand
  • Medipol Mega University Hospital · Istanbul, Turkey (Türkiye)
Show 1 removed
  • Kaohsiung Medical University Hospital · Kaohsiung, Taiwan
Oct 22, 2026
Primary completion
Oct 31, 2026→Oct 31, 2027
Oct 22, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Oct 22, 2026
Enrollment
1900→1526
Oct 22, 2026
Eligibility
Minimum age none→18 Years; 9 inclusion criteria added, 2 removed; 5 exclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • Removedpatient developed clinical symptoms compatible with bloodstream infection, hospital-acquired or ventilator-associated pneumonia (hospital-acquired and ventilator-associated pneumonia should fulfil US CDC NHSN criteria) AND,
  • Removedan appropriate specimen has been received by the participating laboratory - that is, a blood culture bottle showing Gram negative bacilli or a respiratory sample collected for clinical purposes showing Gram negative bacilli on Gram stain;
  • AddedAdult patients aged 18 years or older (21 years or older in Singapore) who meet at least one of the following criteria:
  • AddedAt risk of developing bloodstream infection, hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP) due to Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales; OR
  • AddedBlood culture bottles showing Gram-negative bacilli on Gram stain; OR
  • AddedSuspected HAP or VAP with respiratory specimens showing Gram-negative bacteria on Gram stain.
  • AddedFor randomisation, all of the following criteria must be fulfilled:
  • AddedWritten informed consent obtained from the participant or their authorised representative.
  • AddedAn appropriate blood or respiratory specimen received by the participating microbiology laboratory, with Gram-negative bacilli detected on Gram stain.
  • AddedPatients with HAP or VAP must fulfil the US Centers for Disease Control and Prevention National Healthcare Safety Network (CDC NHSN) criteria.
  • AddedNo exclusion criteria are met.
Exclusion criteria
  • EditedRefractory shock or comorbid condition such that the patient is not expected to survive more than 48 hours; OR,.
  • ChangedBefore where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR,Now Suspected catheter-related bloodstream infection where the implicated vascular catheter cannot be removed.
  • EditedtreatmentTreatment is not with the intentintended to cure the infection; OR,.
  • AddedInfection requiring prolonged antibiotic treatment (more than two weeks).
  • Editedpatient is incarceratedIncarceration in a correctional facility; OR,.
  • Editedpatients previously randomisedPrevious enrolment in thisthe RAPID trial within the lastpreceding 60 days.
  • AddedPatients younger than 18 years (younger than 21 years in Singapore).
Oct 22, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedComposite endpoint of allAll-cause mortality and/Cause Mortality or no improvement inAbsence of SOFA scoreScore Improvement at Day 14 post index cultureTime frame: 14 days post index culture → Day 14 following index culture.
Oct 22, 2026
Secondary outcomes
1 edited, 21 added, 5 removed
What changed in the outcomes
  • AddedClinical Response at Day 7 and Day 14Time frame: Day 7 and Day 14 following index culture
  • AddedAll-Cause Mortality at Day 14, Day 28 and Day 60Time frame: Day 14, Day 28 and Day 60 following index culture
  • AddedFunctional Status and Health-Related Quality of LifeTime frame: Day 14, Day 28 and Day 60 following index culture
  • AddedDesirability of Outcome Ranking (DOOR) at Day 28Time frame: Day 28 following index culture
  • AddedImplementation Costs and Health Economic OutcomesTime frame: Within 60 days following randomisation for within-trial resource utilisation; modelled time horizon to be confirmed.
  • AddedDays Alive and Out of Hospital Within 60 DaysTime frame: Up to Day 60 following index culture
  • AddedLength of Intensive Care Unit StayTime frame: Up to Day 60 following index culture
  • AddedLength of Hospital StayTime frame: Up to Day 60 following index culture
  • AddedDuration of Mechanical VentilationTime frame: Up to Day 60 following index culture
  • AddedType of Accommodation Upon Hospital DischargeTime frame: At hospital discharge, assessed within 60 days following index culture
  • AddedPersistence of Bacteraemia at Day 4Time frame: Day 4 following index culture
  • AddedMicrobiological Growth in Respiratory Cultures at Day 7Time frame: Day 7 following index culture
  • AddedDevelopment of Resistance to Meropenem or Ceftazidime-AvibactamTime frame: Up to Day 28 following index culture
  • AddedIncidence of Acute Kidney InjuryTime frame: Up to Day 28 following index culture
  • AddedIncidence of Clostridioides difficile DiarrhoeaTime frame: Up to Day 28 following index culture
  • AddedTime From Index Culture to Active Antibiotic TherapyTime frame: From index culture collection to initiation of active antibiotic therapy
  • AddedNumber of Days on Antibiotic Treatment Within 28 DaysTime frame: Up to Day 28 following index culture
  • AddedAntibiotic Treatment Modification Following Microbiological DiagnosisTime frame: Within 7 days following microbiological diagnostic results
  • AddedTime to Detection of Carbapenemase Production or Carbapenem ResistanceTime frame: From index specimen collection to reporting of microbiological results
  • AddedTime to Detection of Third-Generation Cephalosporin ResistanceTime frame: From index specimen collection to reporting of microbiological results
  • AddedTime to Identification of Other Multidrug-Resistant Gram-Negative PathogensTime frame: From index specimen collection to reporting of microbiological results
  • RemovedClinical responseTime frame: Day 7 and Day 14 post index culture
  • RemovedAll-cause mortalityTime frame: Day 14, Day 28, and Day 60 post index culture
  • RemovedFunctional outcomeTime frame: Day 14, Day 28 and Day 60 from collection of index culture
  • RemovedComposite outcomeTime frame: Day 28 from index microbiology culture sample
  • RemovedImplementation cost-Health EconomicsTime frame: 60 days since enrolment
  • Changedother outcomeBefore Genomics studiesNow Whole-Genome Sequencing of Causative Bacterial IsolatesTime frame: Day 0 → Baseline (index culture)
Oct 22, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • University Malaya Medical Centre · Kuala Lumpur, MalaysiaContact n•••@gmail.com→h•••@ummc.edu.myContact person changed (no phone or email listed)
  • Taichung Veterans General Hospital · Taichung, TaiwanContact y•••@gmail.com→l•••@gmail.comContact person changed (no phone or email listed)
  • Sunpasitthiprasong Hospital · Ubon Ratchathani, ThailandContact S•••@tropmedres.ac→s•••@gmail.com
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    18 sites added, 1 site removed — first sites in India, Singapore, South Korea and Turkey (Türkiye). 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • University Malaya Medical Centre · Kuala Lumpur, MalaysiaNot yet recruiting→Recruiting
    • Sunpasitthiprasong Hospital · Ubon Ratchathani, ThailandNot yet recruiting→Recruiting
    Show 18 added (4 Malaysia, 4 South Korea, 3 Taiwan, 3 Thailand, 2 Singapore, 1 India, 1 Turkey (Türkiye))
    • Christian Medical College Vellore · Vellore, India
    • Hospital Pulau Pinang · George Town, Malaysia
    • Hospital Raja Permaisuri Bainun · Ipoh, Malaysia
    • Sarawak General Hospital · Kuching, Malaysia
    • Hospital Seberang Jaya · Seberang Jaya, Malaysia
    • National University Hospital · Singapore, Singapore
    • Tan Tock Seng Hospital · Singapore, Singapore
    • Korea University Ansan Hospital · Ansan, South Korea
    • Soonchunhyang University Cheonan Hospital · Cheonan, South Korea
    • Kyungpook National University Chilgok Hospital · Daegu, South Korea
    • Seoul National University Bundang Hospital · Seongnam, South Korea
    • Kaohsiung Medical University Hospital · Kaohsiung City, Taiwan
    • Kaohsiung Veterans General Hospital · Kaohsiung City, Taiwan
    • National Taiwan University Hospital · Taipei, Taiwan
    • Siriraj Hospital · Bangkok, Thailand
    • Songklanagarind Hospital · Hat Yai, Thailand
    • Srinagarind Hospital, Khon Kaen University · Khon Kaen, Thailand
    • Medipol Mega University Hospital · Istanbul, Turkey (Türkiye)
    Show 1 removed
    • Kaohsiung Medical University Hospital · Kaohsiung, Taiwan
    Primary completion Oct 31, 2026→Oct 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    Enrollment 1900→1526
    Eligibility Minimum age none→18 Years; 9 inclusion criteria added, 2 removed; 5 exclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • Removedpatient developed clinical symptoms compatible with bloodstream infection, hospital-acquired or ventilator-associated pneumonia (hospital-acquired and ventilator-associated pneumonia should fulfil US CDC NHSN criteria) AND,
    • Removedan appropriate specimen has been received by the participating laboratory - that is, a blood culture bottle showing Gram negative bacilli or a respiratory sample collected for clinical purposes showing Gram negative bacilli on Gram stain;
    • AddedAdult patients aged 18 years or older (21 years or older in Singapore) who meet at least one of the following criteria:
    • AddedAt risk of developing bloodstream infection, hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP) due to Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales; OR
    • AddedBlood culture bottles showing Gram-negative bacilli on Gram stain; OR
    • AddedSuspected HAP or VAP with respiratory specimens showing Gram-negative bacteria on Gram stain.
    • AddedFor randomisation, all of the following criteria must be fulfilled:
    • AddedWritten informed consent obtained from the participant or their authorised representative.
    • AddedAn appropriate blood or respiratory specimen received by the participating microbiology laboratory, with Gram-negative bacilli detected on Gram stain.
    • AddedPatients with HAP or VAP must fulfil the US Centers for Disease Control and Prevention National Healthcare Safety Network (CDC NHSN) criteria.
    • AddedNo exclusion criteria are met.
    Exclusion criteria
    • EditedRefractory shock or comorbid condition such that the patient is not expected to survive more than 48 hours; OR,.
    • ChangedBefore where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR,Now Suspected catheter-related bloodstream infection where the implicated vascular catheter cannot be removed.
    • EditedtreatmentTreatment is not with the intentintended to cure the infection; OR,.
    • AddedInfection requiring prolonged antibiotic treatment (more than two weeks).
    • Editedpatient is incarceratedIncarceration in a correctional facility; OR,.
    • Editedpatients previously randomisedPrevious enrolment in thisthe RAPID trial within the lastpreceding 60 days.
    • AddedPatients younger than 18 years (younger than 21 years in Singapore).
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedComposite endpoint of allAll-cause mortality and/Cause Mortality or no improvement inAbsence of SOFA scoreScore Improvement at Day 14 post index cultureTime frame: 14 days post index culture → Day 14 following index culture.
    Secondary outcomes 1 edited, 21 added, 5 removed
    What changed in the outcomes
    • AddedClinical Response at Day 7 and Day 14Time frame: Day 7 and Day 14 following index culture
    • AddedAll-Cause Mortality at Day 14, Day 28 and Day 60Time frame: Day 14, Day 28 and Day 60 following index culture
    • AddedFunctional Status and Health-Related Quality of LifeTime frame: Day 14, Day 28 and Day 60 following index culture
    • AddedDesirability of Outcome Ranking (DOOR) at Day 28Time frame: Day 28 following index culture
    • AddedImplementation Costs and Health Economic OutcomesTime frame: Within 60 days following randomisation for within-trial resource utilisation; modelled time horizon to be confirmed.
    • AddedDays Alive and Out of Hospital Within 60 DaysTime frame: Up to Day 60 following index culture
    • AddedLength of Intensive Care Unit StayTime frame: Up to Day 60 following index culture
    • AddedLength of Hospital StayTime frame: Up to Day 60 following index culture
    • AddedDuration of Mechanical VentilationTime frame: Up to Day 60 following index culture
    • AddedType of Accommodation Upon Hospital DischargeTime frame: At hospital discharge, assessed within 60 days following index culture
    • AddedPersistence of Bacteraemia at Day 4Time frame: Day 4 following index culture
    • AddedMicrobiological Growth in Respiratory Cultures at Day 7Time frame: Day 7 following index culture
    • AddedDevelopment of Resistance to Meropenem or Ceftazidime-AvibactamTime frame: Up to Day 28 following index culture
    • AddedIncidence of Acute Kidney InjuryTime frame: Up to Day 28 following index culture
    • AddedIncidence of Clostridioides difficile DiarrhoeaTime frame: Up to Day 28 following index culture
    • AddedTime From Index Culture to Active Antibiotic TherapyTime frame: From index culture collection to initiation of active antibiotic therapy
    • AddedNumber of Days on Antibiotic Treatment Within 28 DaysTime frame: Up to Day 28 following index culture
    • AddedAntibiotic Treatment Modification Following Microbiological DiagnosisTime frame: Within 7 days following microbiological diagnostic results
    • AddedTime to Detection of Carbapenemase Production or Carbapenem ResistanceTime frame: From index specimen collection to reporting of microbiological results
    • AddedTime to Detection of Third-Generation Cephalosporin ResistanceTime frame: From index specimen collection to reporting of microbiological results
    • AddedTime to Identification of Other Multidrug-Resistant Gram-Negative PathogensTime frame: From index specimen collection to reporting of microbiological results
    • RemovedClinical responseTime frame: Day 7 and Day 14 post index culture
    • RemovedAll-cause mortalityTime frame: Day 14, Day 28, and Day 60 post index culture
    • RemovedFunctional outcomeTime frame: Day 14, Day 28 and Day 60 from collection of index culture
    • RemovedComposite outcomeTime frame: Day 28 from index microbiology culture sample
    • RemovedImplementation cost-Health EconomicsTime frame: 60 days since enrolment
    • Changedother outcomeBefore Genomics studiesNow Whole-Genome Sequencing of Causative Bacterial IsolatesTime frame: Day 0 → Baseline (index culture)
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • University Malaya Medical Centre · Kuala Lumpur, MalaysiaContact n•••@gmail.com→h•••@ummc.edu.myContact person changed (no phone or email listed)
    • Taichung Veterans General Hospital · Taichung, TaiwanContact y•••@gmail.com→l•••@gmail.comContact person changed (no phone or email listed)
    • Sunpasitthiprasong Hospital · Ubon Ratchathani, ThailandContact S•••@tropmedres.ac→s•••@gmail.com
    + 6 other changes: index terms, verification date, responsible party, description, arm descriptions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05979545
Collaborators
Pfizer, Biomerieux inc
Responsible party
Mo Yin (Adj A/Prof Mo Yin, National University of Singapore) — Principal investigator
First posted
Aug 7, 2023
Start date
Dec 12, 2023
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Kithalakshmi Vignesvaran
Contact
kitha@nus.edu.sg
90300178
David Paterson, Professor
principal investigator · National University of Singapore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion